Similar articles

• Four-Month Rifapentine Regimens for Tuberculosis.

  Taylor A, Woodrow C. Taylor A, et al. N Engl J Med. 2022 Mar 17;386(11):1095. doi: 10.1056/NEJMc2114483. N Engl J Med. 2022. PMID: 35294822 No abstract available.
• Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

  Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. Rosenthal IM, et al. Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21. Am J Respir Crit Care Med. 2008. PMID: 18723432 Free PMC article.
• Rifapentine: its role in the treatment of tuberculosis.

  Temple ME, Nahata MC. Temple ME, et al. Ann Pharmacother. 1999 Nov;33(11):1203-10. doi: 10.1345/aph.18450. Ann Pharmacother. 1999. PMID: 10573321 Review.
• Rifapentine.

  Jarvis B, Lamb HM. Jarvis B, et al. Drugs. 1998 Oct;56(4):607-16; discussion 617. doi: 10.2165/00003495-199856040-00008. Drugs. 1998. PMID: 9806107 Review.
• Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.

  Vernon A, Burman W, Benator D, Khan A, Bozeman L. Vernon A, et al. Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8. Lancet. 1999. PMID: 10359410 Clinical Trial.